Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3
The experimentally established mechanism targets of Epinephrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 7/20 | 0.96 |
| ▸ | ADRB1 known ✓ | P08588 | 6/20 | 0.93 |
| ▸ | ADRB3 known ✓ | P13945 | 5/20 | 0.93 |
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 0.93 |
| ▸ | ADRA2B known ✓ | P18089 | 3/20 | 0.93 |
| ▸ | ADRA2C known ✓ | P18825 | 3/20 | 0.93 |
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 0.93 |
| ▸ | ADRA1B known ✓ | P35368 | 3/20 | 0.93 |
| ▸ | ADRA1D known ✓ | P25100 | 2/20 | 0.93 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.96 |
| ▸ | BLM | P54132 | 5/20 | 0.96 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.96 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.96 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.93 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.93 |
| ▸ | MAPT | P10636 | 6/20 | 0.93 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.93 |
| ▸ | TSHR | P16473 | 5/20 | 0.93 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.93 |
| ▸ | MEN1 | O00255 | 3/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Racepinephrine SCHEMBL28308045 | 0.98 | KDM4E (0.96) | KDM4EADRB2BLMPMP22NPSR1 | |
| Racepinephrine SCHEMBL16667632 | 0.98 | KDM4E (1.00) | KDM4EADRB2BLMPMP22NPSR1 | |
| Epinephrine SCHEMBL25041 | 0.98 | KDM4E (1.00) | KDM4EADRB2BLMPMP22NPSR1 | |
| Epinephrine SCHEMBL31267207 | 0.98 | KDM4E (1.00) | KDM4EADRB2BLMPMP22NPSR1 | |
| Epinephrine SCHEMBL4980185 | 0.98 | KDM4E (1.00) | KDM4EADRB2BLMPMP22NPSR1 | |
| Epinephrine SCHEMBL4337310 | 0.98 | KDM4E (0.96) | KDM4EADRB2BLMPMP22NPSR1 | |
| L-Adrenaline SCHEMBL4983607 | 0.98 | KDM4E (1.00) | KDM4EADRB2BLMPMP22NPSR1 | |
| Racepinephrine SCHEMBL41370 | 0.98 | KDM4E (1.00) | KDM4EADRB2BLMPMP22NPSR1 | |
| Racepinephrine SCHEMBL31238229 | 0.98 | KDM4E (1.00) | KDM4EADRB2BLMPMP22NPSR1 | |
| Racepinephrine SCHEMBL9614373 | 0.98 | KDM4E (1.00) | KDM4EADRB2BLMPMP22NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2194054-B1 | Ligands for G-protein coupled receptors | CAMBRIDGE ENTPR LTD (GB) | 2014-06-25 | — | — | EP | disclosed |
| US-8618283-B2 | Ligand libraries for screening GPCRs | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2013-12-31 | — | — | US | disclosed |
| US-20130172319-A1 | Alpha-AminoCycloLactam Ligands for G-Protein Coupled Receptors, and Methods of Using Same | Grainger, David J. (GB) | 2013-07-04 | — | — | US | disclosed |
| US-8389279-B2 | α-aminocyclolactam ligands for G-protein coupled receptors, and methods of using same | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2013-03-05 | — | — | US | disclosed |
| EP-2508515-A1 | Ligands for g-protein coupled receptors | Cambridge Enterprise Limited (GB) | 2012-10-10 | — | — | EP | disclosed |
| US-20120046198-A1 | Ligand Libraries for Screening GPCRs | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2012-02-23 | — | — | US | disclosed |
| US-20110288073-A1 | Alpha-Aminocyclolactam Ligands for G-protein Coupled Receptors, and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-24 | — | — | US | disclosed |
| US-8008289-B2 | 4-(Adamantane-1-carbonylamino)-3-oxo-2-aza-bicyclo[2.2.2]octane; compounds enriched in agonist and antagonists; mediating cellular signalling in response to hormones, neurotransmitters, cytokines | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2011-08-30 | — | — | US | disclosed |
| EP-2194054-A1 | Ligands for G-protein coupled receptors | Cambridge Enterprise Ltd. (GB) | 2010-06-09 | — | — | EP | disclosed |
| EP-1786810-B1 | LIGANDS FOR G-PROTEIN COUPLED RECEPTORS | CAMBRIDGE ENTPR LTD (GB) | 2010-03-17 | — | — | EP | disclosed |
| US-20080261948-A1 | Ligands for G-Protein Coupled Receptors | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080161283-A1 | 4-(Adamantane-1-carbonylamino)-3-oxo-2-aza-bicyclo[2.2.2]octane; compounds enriched in agonist and antagonists; mediating cellular signalling in response to hormones, neurotransmitters, cytokines | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2008-07-03 | — | — | US | disclosed |
| EP-1853569-A1 | LIGANDS FOR G-PROTEIN COUPLED RECEPTORS | Cambridge Enterprise Limited (GB) | 2007-11-14 | — | — | EP | disclosed |
| EP-1786810-A1 | LIGANDS FOR G-PROTEIN COUPLED RECEPTORS | Cambridge Enterprise Limited (GB) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006085096-A1 | LIGANDS FOR G-PROTEIN COUPLED RECEPTORS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2006-08-17 | — | — | WO | disclosed |
| WO-2006024815-A1 | LIGANDS FOR G-PROTEIN COUPLED RECEPTORS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261948-A1 | Ligands for G-Protein Coupled Receptors | GRK5, GPR4, GRK4 | ADRB2 57/4885ADRB1 53/4885ADRB3 59/4885 |
| US-20110288073-A1 | Alpha-Aminocyclolactam Ligands for G-protein Coupled Receptors, and Methods of Using Same | NPY1R, GPR139, GPR18 | ADRB2 49/4885ADRB1 11/4885ADRB3 47/4885 |
| US-20130172319-A1 | Alpha-AminoCycloLactam Ligands for G-Protein Coupled Receptors, and Methods of Using Same | GPR139, ARRB1, GPR84 | ADRB2 26/4885ADRB1 6/4885ADRB3 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.